Plasmodium pre-erythrocytic stages: what's new?

Trends in Parasitology

Volumn 24, Issue 12, 2008, Pages 564-569

  Ménard, Robert ^a   Heussler, Volker ^b   Yuda, Masao ^c   Nussenzweig, Victor ^d  

^a INSTITUT PASTEUR   (France)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICALLY ATTENUATED SPOROZOITE VACCINE; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

DISEASE COURSE; ERYTHROCYTE; HUMAN; LIFE CYCLE; LIVER CELL; MALARIA; MEROZOITE; NONHUMAN; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM YOELII; REVIEW; SPOROZOITE;

ANIMALS; GENE EXPRESSION REGULATION; HOST-PARASITE INTERACTIONS; MALARIA VACCINES; PLASMODIUM; PROTOZOAN PROTEINS;

EID: 55549137997     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.08.009     Document Type: Review

References (73)

1. Florens L., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419 (2002) 520-526
2. Le Roch K.G., et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Genome Res. 14 (2004) 2308-2318
3. Hall N., et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 307 (2005) 82-86
4. Ishino T., et al. Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer. PLoS Biol. 2 (2004) E4
5. Ishino T., et al. A Plasmodium sporozoite protein with a membrane attack complex domain is required for breaching the liver sinusoidal cell layer prior to hepatocyte infection. Cell. Microbiol. 7 (2005) 199-208
6. Kariu T., et al. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol. Microbiol. 59 (2006) 1369-1379
7. Matuschewski K., et al. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J. Biol. Chem. 277 (2002) 41948-41953
8. Kaiser K., et al. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol. Microbiol. 51 (2004) 1221-1232
9. Rosinski-Chupin I., et al. Serial analysis of gene expression in Plasmodium berghei salivary gland sporozoites. BMC Genomics 8 (2007) 466
10. Wang Q., et al. Transcriptome of axenic liver stages of Plasmodium yoelii. Mol. Biochem. Parasitol. 137 (2004) 161-168
11. Sacci Jr. J.B., et al. Transcriptional analysis of in vivo Plasmodium yoelii liver stage gene expression. Mol. Biochem. Parasitol. 142 (2005) 177-183
12. Grüner A.C., et al. Insights into the P. yoelii hepatic stage transcriptome reveal complex transcriptional patterns. Mol. Biochem. Parasitol. 142 (2005) 184-192
13. Tarun A.S., et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl Acad. Sci. USA 105 (2008) 305-310
14. Young J.A., et al. In silico discovery of transcription regulatory elements in Plasmodium falciparum. BMC Genomics 9 (2008) 70
15. Balaji S., et al. Discovery of the principal specific transcription factors of Apicomplexa and their implication for the evolution of the AP2-integrase DNA binding domains. Nucleic Acids Res. 33 (2005) 3994-4006
16. Amino R., et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12 (2006) 220-224
17. Amino R., et al. Imaging malaria sporozoites in the dermis of the mammalian host. Nat. Protoc. 2 (2007) 1705-1712
18. Yamauchi L.M., et al. Plasmodium sporozoites trickle out of the injection site. Cell. Microbiol. 9 (2007) 1215-1222
19. Vanderberg J.P., and Frevert U. Intravital microscopy demonstrating antibody-mediated immobilization of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34 (2004) 991-996
20. Tardieux I., and Ménard R. Migration of Apicomplexa across biological barriers: the Toxoplasma and Plasmodium rides. Traffic 9 (2008) 627-635
21. Demeure C.E., et al. Anopheles mosquito bites activate cutaneous mast cells leading to a local inflammatory response and lymph node hyperplasia. J. Immunol. 174 (2005) 3932-3940
22. Amino R., et al. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe 3 (2008) 88-96
23. Chakravarty S., et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13 (2007) 1035-1041
24. Mota M.M., et al. Migration of Plasmodium sporozoites through cells before infection. Science 291 (2001) 141-144
25. Mota M.M., and Rodriguez A. Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host. Cell. Microbiol. 6 (2004) 1113-1118
26. Bhanot P., et al. A surface phospholipase is involved in the migration of Plasmodium sporozoites through cells. J. Biol. Chem. 280 (2005) 6752-6760
27. Moreira C.K., et al. The Plasmodium TRAP/MIC2 family member, TRAP-like protein (TLP), is involved in tissue traversal by sporozoites. Cell. Microbiol. 10 (2008) 1505-1516
28. Kumar K.A., et al. Exposure of Plasmodium sporozoites to the intracellular concentration of potassium enhances infectivity and reduces cell passage activity. Mol. Biochem. Parasitol. 156 (2007) 32-40
29. Coppi A., et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2 (2007) 316-327
30. Silvie O., et al. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat. Med. 9 (2003) 93-96
31. Silvie O., et al. Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell. Microbiol. 8 (2006) 1134-1146
32. Coppi A., et al. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 201 (2005) 27-33
33. Silvie O., et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 279 (2004) 9490-9496
34. Ishino T., et al. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol. Microbiol. 58 (2005) 1264-1275
35. van Dijk M.R., et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl Acad. Sci. USA 102 (2005) 12194-12199
36. Labaied M., et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 75 (2007) 3758-3768
37. Labaied M., et al. Depletion of the Plasmodium berghei thrombospondin-related sporozoite protein reveals a role in host cell entry by sporozoites. Mol. Biochem. Parasitol. 153 (2007) 158-166
38. Mueller A.K., et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167
39. Mueller A.K., et al. Plasmodium liver stage development arrest by depletion of a protein at the parasite-host interface. Proc. Natl Acad. Sci. USA 102 (2005) 3022-3027
40. Mikolajczak S.A., et al. L-FABP is a critical host factor for successful malaria liver stage development. Int. J. Parasitol. 37 (2007) 483-489
41. Aly A.S., et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol. 69 (2008) 152-163
42. van de Sand C., et al. The liver stage of Plasmodium berghei inhibits host cell apoptosis. Mol. Microbiol. 58 (2005) 731-742
43. Sturm A., et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313 (2006) 1287-1290
44. Sturm A., and Heussler V. Live and let die: manipulation of host hepatocytes by exoerythrocytic Plasmodium parasites. Med. Microbiol. Immunol. 196 (2007) 127-133
45. Schmidt-Christensen A., et al. Expression and processing of Plasmodium berghei SERA3 during liver stages. Cell. Microbiol. 10 (2008) 1723-1734
46. Aly A.S., and Matuschewski K. A malarial cysteine protease is necessary for Plasmodium sporozoite egress from oocysts. J. Exp. Med. 202 (2005) 225-230
47. Miller S.K., et al. A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle. J. Biol. Chem. 277 (2002) 47524-47532
48. Thiberge S., et al. In vivo imaging of malaria parasites in the murine liver. Nat. Protoc. 2 (2007) 1811-1818
49. Baer K., et al. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog. 3 (2007) e171
50. Marti M., et al. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 306 (2004) 1930-1933
51. Hiller N.L., et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 306 (2004) 1934-1937
52. Singh A.P., et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131 (2007) 492-504
53. Hill A.V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6 (2006) 21-32
54. Todryk S.M., and Hill A.V. Malaria vaccines: the stage we are at. Nat. Rev. Microbiol. 5 (2007) 487-489
55. Bojang K.A. RTS,S/AS02A for malaria. Expert Rev. Vaccines 5 (2006) 611-615
56. Sacarlal J., et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26 (2008) 174-184
57. Aponte J.J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 370 (2007) 1543-1551
58. Alonso P.L., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
59. Dunachie S.J., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccine RTS,S/AS02A and MVA-CS. Vaccine 24 (2006) 2850-2859
60. Heppner D.G., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 (2005) 2243-2250
61. Moorthy V.S., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1 (2004) e33
62. Bejon P., et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2 (2007) e707
63. Hoffman S.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185 (2002) 1155-1164
64. Doolan D.L., and Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165 (2000) 1453-1462
65. Kumar K.A., et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444 (2006) 937-940
66. Matuschewski K. Hitting malaria before it hurts: attenuated Plasmodium liver stages. Cell. Mol. Life Sci. 64 (2007) 3007-3011
67. Mikolajczak S.A., et al. Preerythrocytic malaria vaccine development. Curr. Opin. Infect. Dis. 20 (2007) 461-466
68. + T cells. J. Infect. Dis. 196 (2007) 608-616
69. Scheller L.F., and Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl Acad. Sci. USA 92 (1995) 4066-4068
70. Hafalla J.C.R., et al. Short-term antigen presentation and single clonal burst limit the magnitude of the CD8+ T cell responses to the malaria liver stages. Proc. Natl Acad. Sci. USA 99 (2002) 11819-11824
71. Mueller A.K., et al. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am. J. Pathol. 171 (2007) 107-115
72. Chakravarty S., et al. Effector CD8+ T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect. Immun. 76 (2008) 3628-3631
73. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206 (2003) 3803-3808